Treatment Efficacy for Drug Abuse and AIDS Prevention - 1
Sponsor
National Institute on Drug Abuse (NIDA) (NIH)
Overall Status
Completed
CT.gov ID
NCT00000210
Collaborator
Mclean Hospital (Other)
0
1
77
0
Study Details
Study Description
Brief Summary
The purpose of this study is to assess the safety and effectiveness of buprenorphine for treatment of concurrent intravenous heroin and cocaine dependence.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
| Phase 2 |
Study Design
Study Type:
Interventional
Primary Purpose:
Treatment
Official Title:
Treatment Efficacy for Drug Abuse and AIDS Prevention
Study Start Date
:
Sep 1, 1989
Actual Primary Completion Date
:
Feb 1, 1996
Actual Study Completion Date
:
Feb 1, 1996
Outcome Measures
Primary Outcome Measures
Eligibility Criteria
Criteria
Ages Eligible for Study:
26 Years
to 41 Years
Sexes Eligible for Study:
Male
Accepts Healthy Volunteers:
No
Please contact site for information.
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | McLean Hospital, Dept. of Psychiatry | Belmont | Massachusetts | United States | 2178 |
Sponsors and Collaborators
- National Institute on Drug Abuse (NIDA)
- Mclean Hospital
Investigators
- Principal Investigator: Jack Mendelson, M.D., Mclean Hospital
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.Responsible Party:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00000210
Other Study ID Numbers:
- NIDA-06116-1
- R18-06116-1
First Posted:
Sep 21, 1999
Last Update Posted:
Jan 12, 2017
Last Verified:
Dec 1, 2002
Keywords provided by National Institute on Drug Abuse (NIDA)
Additional relevant MeSH terms: